title: Effect of acitretin on wound healing in organ transplant recipients.
abstract: BACKGROUND
  Systemic retinoids possess significant benefits in cutaneous malignancy chemoprevention; however, retinoids have been associated with excessive granulation tissue and hypertrophic scarring.
  
  
  OBJECTIVE
  The objective of this study was to assess wound healing outcomes in organ transplant recipients, both with and without the concomitant use of systemic acitretin chemoprophylaxis.
  
  
  METHODS
  Twenty-nine immunosuppressed organ transplant recipients underwent treatment of basal cell or squamous cell carcinoma by Mohs or excisional surgery, with a total of 85 wounds. Wounds were evaluated postoperatively at early (average 12.9 days) and late (average 75.8 days) time points. Endpoints for all wounds included infection, hypertrophic granulation tissue, and hypertrophic scarring. Reconstructed wounds were also evaluated for dehiscence.
  
  
  RESULTS
  Eleven patients taking oral acitretin had 41 wounds, of which 33 were reconstructed and 8 healed by second intention. The 18 patients not taking acitretin (control group) had a total of 44 wounds, of which 33 were reconstructed and 11 healed by second intention. There were no statistically significant differences between the acitretin group and the control group in the incidences of infection, dehiscence, hypertrophic granulation tissue, or hypertrophic scarring at early or late evaluation points.
  
  
  CONCLUSIONS
  Systemic acitretin chemoprophylaxis does not appear to increase the risk of wound healing complications in organ transplant recipients.
authors.affiliation: Cutaneous Surgery and Laser Center, Department of Dermatology, University of Minnesota, USA. srtan@iupui.edu
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Tan
authors.forename: Whitney D
authors.initials: WD
authors.lastname: Tope
mesh_terms: D017255:Acitretin / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D018890:Chemoprevention / Q000379:methods; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects; D010865:Pilot Projects; D012878:Skin Neoplasms / Q000209:etiology / Q000517:prevention & control* / Q000601:surgery; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects* / Q000276:immunology
chemical_list: D016588:Anticarcinogenic Agents; D017255:Acitretin